Cucumbers Recalled After Salmonella Outbreak Sickens 20
The Food and Drug Administration (FDA) announced a recall on Monday for cucumbers grown by Florida-based company Bedner Growers Inc. after an outbreak of Salmonella Montevideo, a bacterial disease that affects the intestinal tract, sickened more than 2 dozen people across multiple states.
According to the news release from the FDA, recalled cucumbers were distributed to retailers and distribution centers between April 29 and May 19. As of Tuesday, 26 people across 15 states have become ill from the outbreak, 9 of whom required hospitalization, according to the Centers for Disease Control and Prevention (CDC). Of those interviewed by the FDA, 11 said they ate cucumbers prior to becoming sick.
FDA investigators collected an environmental sample from Bedner Growers back in April, which tested positive for salmonella and matched samples from people who had recently fallen ill, the report states. The follow-up inspection was in response to a 2024 salmonella outbreak also linked to cucumbers grown at Bedner Growers Inc.
Additional recalls are being conducted by companies that used or repackaged recalled cucumbers grown by Bedner Growers, Inc, including the following:
Harris TeeterExternal Link Disclaimer – fresh cucumbers and vegetable trays
Kroger - Yummi Sushi-branded products
PennRose Farms, LLC - 5-pound mesh bags of whole cucumbers
Ukrop's Homestyle Foods, LLC - Marinated Cucumber salads
Some potentially contaminated cucumbers were available at Bedner's Farm Fresh Market in three different Florida locations including Boynton Beach, Delray Beach, and West Palm Beach, according to the FDA.
As of May 20, the outbreak linked to the recalled cucumbers has sickened more than 2 dozen people in the following 15 states: Alabama, California, Colorado, Florida, Illinois, Kansas, Kentucky, Michigan, North Carolina, New York, Ohio, Pennsylvania, South Carolina, Tennessee and Virginia.
The status of the investigation is ongoing at this time. Click here for updates from the FDA as new information is released.
Cucumbers Recalled After Salmonella Outbreak Sickens 20 first appeared on Men's Journal on May 23, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Blue states call on FDA to expand abortion pill access
Attorneys general of New York, California, New Jersey and Massachusetts are asking the Food and Drug Administration (FDA) to expand access to the abortion pill and remove some 'unnecessary' drug restrictions that have been in place for more than two decades. The joint petition, filed Thursday, comes days after FDA Commissioner Marty Makary committed to reviewing the abortion drug amid pressure from Department of Health and Human Services Secretary Robert F. Kennedy Jr. and some Republican lawmakers. The FDA first approved of the use of mifepristone and misoprostol for an abortion in 2000. Unlike surgical abortions, medication abortions do not need to take place in a clinical setting, and patients are able to take the pills at home. Most abortions in the U.S. are now medication abortions, according to data from the reproductive health and rights group Guttmacher Institute. In 2023, 63 percent of all abortions in the U.S. were medication abortions. The safety of mifepristone has come under increased scrutiny by some Republican lawmakers, citing a flawed study claiming the rate of adverse health events that occur among patients is far higher than previously reported. More than 100 scientific studies have been conducted looking at the safety and efficacy of mifepristone and misoprostol; all of them have found that the drugs are a safe way to terminate a pregnancy. 'Given Mifepristone's 25-year safety record, there is simply no scientific or medical reason to subject it to such extraordinary restrictions,' New York Attorney General Letitia James said. 'The FDA must follow the science and lift these unnecessary barriers that put patients at risk and push providers out of care.' Mifepristone's use is subject to a Risk Evaluation and Mitigation Strategy (REMS) program under the FDA. The attorneys general argue three requirements under the REMS program for the drug should be removed since they pose a burden to patients and health care systems. The first is related to prescriber certification. As part of the REMS program, health care providers who prescribe mifepristone are required to add their names to national and abortion provider lists, which the attorneys general say raise 'serious safety and legal concerns.' The second has to do with patient agreement forms. All patients who want mifepristone — even those using the drug to treat a miscarriage — are required to sign a document stating they are using the drug to end a pregnancy. The third requirement mentioned in the petition is connected to pharmacy certification. As part of mifepristone's REMS program, pharmacies that carry the drug are subject to tracking, shipping and reporting requirements, which the attorneys general argue may 'dissuade' some from carrying the drug. The FDA has yet to reply to a request for comment from The Hill about the petition. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
New York Times
43 minutes ago
- New York Times
How to Protect Yourself From Saharan Dust
A plume of dust that has traveled across the Atlantic Ocean from the Sahara was affecting air quality in Florida on Thursday and may reach other Southern states by the weekend. Such events occur in the Caribbean and the Gulf Coast region several times a year, and scientists are studying how climate change may affect their frequency and intensity. Here is what research shows about the health effects of Saharan dust exposure, and how people can protect themselves. What is in the dust plume? Dust plumes like this one originate in deserts, in this case, the Sahara. The dust is composed mainly of minerals found in desert sand, including silicates such as quartz. But as they travel, plumes can pick up other pollutants, as well as bacteria, viruses and fungi. Reactions among the pollutants, and between those pollutants and sunlight, can produce additional chemicals as well. What are the effects of exposure? What makes Saharan dust dangerous is that its particles are extremely small, which means they can be inhaled deep into the lungs, irritating and damaging them. Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
Opinion: When the insulin that works disappears
I remember being in a college pathology class when the professor told us we should learn about type 1 diabetes, since it was likely to impact someone we knew. Then he said something else that I didn't fully understand at the time: the insulin market was becoming more concentrated, with fewer companies producing it, which was leading to fewer options and rising prices. Fast forward nearly 30 years later, and my 13-year-old daughter was diagnosed with type 1 diabetes. We struggled at first. But after a few difficult months, we found a system that worked — involving lifestyle changes and the use of a specific long-acting insulin called Levemir (detemir). Levemir has a shorter and more predictable action than the few alternative long-acting insulins. That made it ideal for my daughter, an athlete navigating not just intense physical activity but also the fluctuating insulin needs that come with puberty and hormone fluctuations. We found a rhythm and felt in control again. Then, two years into her diagnosis, that sense of control was ripped away. On November 8, 2023, we learned that Novo Nordisk planned to discontinue Levemir in the U.S. I was shocked. Levemir had been widely available since 2005. Surely, I thought, someone would step in to fix this. But the more I learned, the more alarmed I became. Levemir is the long-acting insulin that has been most proven safe in pregnancy, where maintaining tight blood glucose control can help prevent early delivery, high blood pressure and large birth weight. Removing it from the market could put pregnant women with diabetes at real risk. I connected with physicians and advocates who were sounding the alarm. I started a petition. I joined with others also affected, and we formed a nonprofit — The Alliance to Protect Insulin Choice — and began traveling to Washington, D.C., often to meet with congressional and regulatory offices. Largely due to our efforts, a company is now seeking to manufacture a biosimilar version of Levemir. But funding has been difficult. Historically, no insulin removed from the market has successfully come back as a biosimilar, and the regulatory path remains unclear. That must change — especially for a drug so critical to pregnancy and pediatric care. Levemir isn't just a niche preference. It was the 127th most prescribed drug and used by just under one million people in 2022. It's still available in other countries. It's the only long-acting insulin that can be diluted, making it vital for infants and small children who need extremely precise doses. It also leads to less weight gain than its alternatives and causes less discomfort during injection because it isn't acidic. The FDA knows that not every drug works the same for every person. Just last year, in response to a penicillin shortage, the agency worked with manufacturers, explored foreign supply chains and increased domestic production. We're asking for the same urgency. We need the FDA to act — to ask Novo Nordisk to permit U.S. access to Levemir from abroad, and to support the company trying to bring a generic version to market. Insulin is not optional. Less than half of people who require insulin use insulin pumps, and many pump users rely on long-acting insulin as a backup. Without Levemir, many patients will be forced onto one of the few alternatives that might not work as well for their bodies and lives. Imagine if a common pain reliever was suddenly pulled from the market — not for safety reasons, but because it was no longer as profitable. There would be outrage. So why is there so little outcry when this happens to a drug that literally keeps people alive? We're asking for fairness, for choice and for a healthcare system that puts patients before profits.
